DexCom’s Growth Story Needs Proof — A Tactical Short Against Expectations
DexCom has high-potential product catalysts (G7 15-day and OTC Stelo expansion) and a bold 2030 plan, but current valuation and mixed technicals leave a window for a tactical short. Enter around $68.86, target $58.00, stop $75.00; horizon mid term (45 trading days).